RAPP — Rapport Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2012593 ·
Last close
$23.76
Market Cap
$1.41B
52W High
$52.93
52W Low
$22.06
ADV30
1,197,969
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -44,086,000 | -40,235,000 | 418,558,000 | 74,754,000 | 27,368,000 |
| Jun 2026 | 0 | — | -60,806,000 | -56,615,000 | 458,982,000 | 63,612,000 | 36,056,000 |
| Mar 2026 | 20,000,000 | — | -24,215,000 | -19,857,000 | 497,597,000 | 78,056,000 | 26,085,000 |
| Dec 2025 | 0 | — | -38,509,000 | -33,763,000 | 512,431,000 | 52,645,000 | 27,778,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-120,850,000
Investing CF
$-59,719,000
Financing CF
$3,964,000
CapEx
$-467,000
Dividends Paid
—
Buybacks
$-5,000
EPS Diluted TTM
$-3.17
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-351,935,000
Inventory
—
Receivables
$171,000
ST Investments
$320,275,000
EBIT TTM
$-167,616,000
Pretax Income TTM
$-150,470,000
Interest Exp TTM
—
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$20,000,000
EBITDA
$-166,714,000
Free Cash Flow
$-75,277,000
Enterprise Value
$1,063,156,160
Total Cash
$395,028,992
Total Debt
$9,391,000
Shares Out
59,279,630
Trailing EPS
$-3.17
Book Value
$8.13
ROE
-33.3%
ROA
-22.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -125,099,000 | -111,483,000 | 512,431,000 | 27,778,000 | 484,653,000 | -87,473,000 |
| Dec 2024 | 0 | -83,055,000 | -78,307,000 | 314,933,000 | 9,506,000 | 305,427,000 | -64,828,000 |
| Dec 2023 | 0 | -36,179,000 | -34,786,000 | 155,423,000 | 181,057,000 | -25,634,000 | -27,181,000 |
| Dec 2022 | — | — | — | 31,603,000 | 41,665,000 | -10,062,000 | — |
TTM Snapshot
Revenues TTM
$27,807,000
NetIncome TTM
$-137,160,000
OpCashFlow TTM
—
Assets (Latest)
$458,982,000
Forward EPS
$-4.15
Max Pain — expiry 2026-12-18
max pain strike: $25.00 · spot: $23.40 · call oi: 2,672 · put oi: 515
Expected Move to 2026-12-18:
±$4.25
(18.16%) —
implied range
$19.15 –
$27.65
· ATM straddle on $22.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DMRA | Damora Therapeutics, Inc. | $1.40B | $22.56 | — |
| NBTX | Nanobiotix S.A. | $1.39B | $27.45 | — |
| NUVB | Nuvation Bio Inc. | $1.37B | $3.90 | — |
| PCRX | Pacira BioSciences, Inc. | $1.46B | $36.48 | — |
| QURE | uniQure N.V. | $1.46B | $20.78 | — |
News headlines (Yahoo Finance, 1h cache)
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
2026-11-04 12:00 · Yahoo
Rapport Therapeutics to Participate in Upcoming Investor Conferences
2026-11-03 12:00 · Yahoo
Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, a
2026-11-02 12:00 · Yahoo
Rapport Therapeutics Prices Stock, Convertible Notes Offerings; Private Placement; Shares Fall
2026-10-28 14:59 · Yahoo
Rapport Therapeutics stock tumbles on $350M capital raise
2026-10-28 13:45 · Yahoo
Rapport Therapeutics Sinks 22% on Discounted $350 Million Stock and Convertible Note Raise
2026-10-28 13:03 · Yahoo
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
2026-10-28 10:00 · Yahoo
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
2026-10-27 20:32 · Yahoo
Rapport Therapeutics (RAPP) Could Be 62% Below Fair Value Following Phase 2 Mania Data
2026-10-23 08:11 · Yahoo
Rapport Therapeutics (RAPP) Stock Gets Fair Value Boost After RAP 219 Bipolar Mania Data
2026-10-23 00:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.